PCRX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PC

Mkt Cap

$1.45B

Volume

638.74K

Next Earnings

November 5th

Loading chart

PC

PCRXPacira BioSciences, Inc. Common Stock

PCRX

Pay with—

Available Balance0.00

PC

Mkt Cap

$1.45B

Volume

638.74K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioViatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio.Zacks Investment Research · Oct 9, 2026

Why Pacira BioSciences Skyrocketed TodayPacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business.The Motley Fool · Oct 8, 2026

PCRX Expands Exparel Commercial Reach in Europe Through Molteni DealPacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201.Zacks Investment Research · Oct 6, 2026

Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?Pacira (PCRX) reported Q2 2026 adjusted earnings of 73 cents per share, beating consensus estimates of 64 cents, with revenues of $192.4 million exceeding expectations. However, the company lowered its 2026 total revenue guidance to $735-$760 million from $745-$770 million following the divestiture of iovera to Zimmer Biomet. Despite the earnings beat, estimates have been trending downward, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.Zacks Investment Research · Sep 3, 2026

Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026Pacira BioSciences announced it will report its second quarter 2026 financial results on August 4, 2026, followed by a live conference call and webcast at 4:30 p.m. ET. The company is a leader in non-opioid pain therapies with three commercial-stage treatments: EXPAREL, ZILRETTA, and iovera, plus a pipeline of clinical-stage assets including PCRX-201 in Phase 2 development for osteoarthritis.GlobeNewswire Inc. · Jul 22, 2026

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Pacira BioSciences granted inducement equity awards to ten new employees on July 2, 2026, consisting of stock options for 9,200 shares and restricted stock units for 18,200 shares. The awards were approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4) without stockholder approval.GlobeNewswire Inc. · Jul 8, 2026

Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsightThe osteoarthritis market is projected to grow at a 3% CAGR from 2026 to 2036, reaching USD 32.5 billion in 2025 across seven major markets. Growth is driven by an aging population, rising disease prevalence, and the launch of emerging therapies including LEVI-04, ZILOSUL, TissueGene-C, and AMZ001. Current treatment is dominated by opioids, but novel disease-modifying therapies and regenerative medicine approaches are expected to reshape the market landscape.GlobeNewswire Inc. · Jun 15, 2026

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Pacira BioSciences announced inducement equity awards to ten new employees on May 4, 2026, including stock options for 36,800 shares and restricted stock units for 27,700 shares. The awards were granted under the company's Amended and Restated 2014 Inducement Plan with an exercise price of $24.69 per share.GlobeNewswire Inc. · May 8, 2026

Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings ReleasePacira BioSciences CFO Shawn Cross exercised and sold 12,941 shares for approximately $326,000 on April 23, 2026, representing 10.94% of his direct holdings. The transaction was part of a pre-planned Rule 10b5-1 trading plan. Despite the insider sale, the company reported strong Q1 2026 results with $177 million in revenue (5% YoY growth) and beat analyst expectations, with the stock rising about 12% in April.The Motley Fool · May 1, 2026

Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty ProceduresPacira BioSciences presented real-world data demonstrating that EXPAREL (bupivacaine liposome injectable suspension) is associated with lower total healthcare costs and reduced opioid utilization in outpatient total hip and knee arthroplasty procedures. Three studies showed cost savings ranging from $7,332 to $13,022 over 6 months post-surgery, with a projected cumulative cost difference of $117,868 per 1 million members by year 3 compared to ropivacaine.GlobeNewswire Inc. · Apr 13, 2026

to start trading

PC

PCRXPacira BioSciences, Inc. Common Stock

PCRX

Pay with—

Available Balance0.00

Your PositionYou don't own any PCRX yet.

Related Tickers

Earnings